The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Feb. 16, 2016
Applicant:

University of Florida Research Foundation, Incorporated, Gainesville, FL (US);

Inventors:

William W. Hauswirth, Gainesville, FL (US);

Sanford L. Boye, Gainesville, FL (US);

Daniel M. Lipinski, Milwaukee, WI (US);

Michael E. Boulton, Chelsea, AL (US);

Shannon E. Boye, Gainesville, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 9/78 (2006.01); A61K 38/50 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 14/705 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 38/50 (2013.01); A61K 48/0058 (2013.01); C07K 14/005 (2013.01); C07K 14/705 (2013.01); C12N 7/00 (2013.01); C12N 9/78 (2013.01); C12Y 305/04016 (2013.01); A61K 38/00 (2013.01); C12N 2750/14121 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2830/008 (2013.01); C12N 2830/15 (2013.01); C12N 2830/85 (2013.01);
Abstract

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from Type I diabetes. Also disclosed are methods for systemic and tissue-localized delivery of therapeutic rAAV-based gene expression cassettes to vascular endothelial cells, tissues, and organs, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of vasculitis, and complications arising from Type I diabetes, such as macular edema, nephropathy, diabetic retinopathy, and the like.


Find Patent Forward Citations

Loading…